Pharmacokinetics and Pharmacodynamics of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Phase 2 Trials for Dose Selection in the Pivotal Phase 3 Trial

Susan E. Shoaf, Arlene B. Chapman, Vicente Torres, John Ouyang, Frank S. Czerwiec

Research output: Contribution to journalArticle

13 Scopus citations

Fingerprint Dive into the research topics of 'Pharmacokinetics and Pharmacodynamics of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Phase 2 Trials for Dose Selection in the Pivotal Phase 3 Trial'. Together they form a unique fingerprint.

Medicine & Life Sciences